Developer docs
API playgroundTry for free, no card

Search company profiles

AmberGen

Full company profile

uuid00033i8

Namestring
AmberGen
Legal namestring
Ambergen Inc.
Websiteurl
ambergen.com
Company typeenum
Private
Founded yearint
1993
Descriptiontext

AmberGen is a privately held, Boston-area biotechnology tools company founded in 1993 to commercialize photocleavable chemistry developed in Professor Kenneth Rothschild's laboratory at Boston University. Its core platform is the patented Miralys MALDI-IHC (Matrix-Assisted Laser Desorption/Ionization Immunohistochemistry) spatial biology imaging system, which uses Photocleavable Mass Tags (PCMTs) — peptide mass-tags attached to antibodies via photocleavable linkers — to enable simultaneous MALDI-MS detection of up to 150+ intact protein biomarkers in a single 45-minute scan, without iterative cycling. The platform is compatible with Bruker rapifleX and timsTOF fleX MALDI-MS instruments and works on both fresh frozen and FFPE tissue, supporting correlative immunofluorescence through optional dual-label probes and combining with native multiomic imaging of unlabeled metabolites, lipids, glycans, and small-molecule drugs on the same tissue section.

AmberGen monetizes the platform through three primary channels: (1) reagent sales — Miralys Probes, Miralys Panels (TurboPlex pre-mixed and VersaPlex configurable formats), Miralys Starter Kits (UV light box, 6-plex validation probes, FFPE slides, and complementary application-scientist onboarding), and Miralys Antibody Conjugation Kits covering 100 PCMT codes; (2) full-service MaxOmic Laboratory multiomic spatial biology imaging and analysis on a fee-for-service basis; and (3) technology licensing of its PC-Biotin, PC-Phosphoramidites, and PC-Linker chemistries to OEM partners including SomaLogic (now Standard BioTools), Promega, Thermo Fisher Scientific, Glen Research, and Link Technologies. Distribution is a hybrid direct/distributor model — direct sales to pharma, biotech, and academic core facilities in North America and globally, with regional distributors in Japan, Korea, Australia, and the UK, plus research-services marketplaces (ScienceExchange, Scientist.com) and a Miralys-enabled service-lab network at MTAC (Washington University), TU Wien, UT Austin, and the University of Victoria.

The company has been non-dilutively financed through approximately $11.5M of NIH SBIR grants across NIA, NCI, NIAID, and NIGMS, and accepted a strategic minority investment from Bruker Corporation in April 2022 alongside additional MassVentures-backed funding rounds of $100K (June 2022) and $200K (May 2023). Customer concentration is diversified across academic translational centers, pharma/biotech drug development teams, and reagent OEM licensees; segment focus spans neuroscience, immuno-oncology, and clinical pathology applications.

Short descriptiontext

AmberGen commercializes the patented Miralys MALDI-IHC spatial biology platform, using Photocleavable Mass Tag chemistry to image 150+ proteins, metabolites, lipids, glycans, and drugs on a single tissue section, serving academic core facilities, pharma/biotech drug developers, and diagnostic reagent licensees worldwide.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBillerica, United States
HQ citystring
Billerica
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
spatial biology imaging, mass spectrometry reagents, photocleavable mass tags, multiplex immunohistochemistry, drug colocalization imaging
Industry3 codes
PRIMARYHLAAAMAI
Molecular Pathology & Tissue Biomarkers (IHC/ISH, digital pathology-linked markers)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAALAI
Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays)
SECONDARYHLAGANAB
Proteomics & Mass Spectrometry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical Laboratories621511
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Spatial Biology Imaging
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Miralys Reagent Sales
TypeOne Time License
Description

Sale of Miralys imaging reagents including photocleavable mass-tag probes, pre-configured panels (TurboPlex™ pre-mixed and VersaPlex™ configurable formats), and antibody conjugation kits. Reagents are sold directly and through distributors in Japan, Korea, Australia, and the UK.

ambergen.com
2MaxOmic Laboratory Services
TypeProfessional Services
Description

AmberGen's full-service MaxOmic™ Laboratory provides multiomic spatial biology imaging and analysis as a service, including spatial proteomics, lipidomics, glycomics, metabolomics, and pharma imaging on the same sample. Results are delivered with a detailed project report including descriptive statistics, pairwise colocalization analysis, clustering analysis, and thumbnail grid images.

ambergen.com
3Technology Licensing
TypeLicensing Royalties
Description

Licensing of AmberGen's photocleavable technology (PC-biotin phosphoramidites, PC-Linkers) to third-party reagent companies such as SomaLogic (for the SomaScan proteomics platform), Promega (fluorescent tRNA products), Thermo-Fisher (PC-Biotin-NHS), Glen Research (phosphoramidite DNA-labeling reagents), and Link Technologies (European distribution).

ambergen.com
4Starter Kits and Training Services
TypeOne Time License
Description

One-time sale of Miralys Starter Kits (UV photocleavage light box, 6-plex validation probe mix, pre-stained and unstained FFPE tissue slides) bundled with complimentary onboarding videoconferences and follow-up image review sessions. Additional on-site training sessions available for purchase.

ambergen.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels7 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Starter Kit for new Miralys users
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Kit includes UV-photocleavage light box, 6-plex probe mix (Neurology or Immunology tissue type), 1 pre-stained and 2 unstained FFPE slides, and all small laboratory items. Bundled with pre-staining and post-staining videoconferences with AmberGen Applications Scientists. Price not publicly disclosed.

ambergen.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 6 records shown
1MaxOmic Laboratory
Description

AmberGen's full-service laboratory providing cutting-edge multiomic spatial biology techniques for imaging a wide range of molecules and cells in their native tissue environment.

ambergen.com
+5 more records
Core offering1 text field

AmberGen develops and sells the Miralys MALDI-IHC spatial biology imaging platform, including Photocleavable Mass Tag (PCMT) antibody probes, pre-configured panels, antibody conjugation kits, and starter kits that enable ultra-high-plex (150+ proteins) imaging of tissues on standard MALDI mass spectrometers. The company also operates the MaxOmic Laboratory, a fee-for-service offering that delivers full-service multiomic spatial imaging and analysis (proteins, lipids, glycans, metabolites, transcripts, and drugs on the same sample).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 150+ intact protein biomarkers can be imaged in as fast as 45 minutes per 1 cm² tissue sample, with scan duration independent of multiplexity
+4 more records
Product overview1 text field

AmberGen offers the Miralys platform as its core product line for spatial biology research. The platform centers on patented Photocleavable Mass Tag (PCMT) technology that enables hyperplex MALDI-IHC (Immunohistochemistry) imaging of up to 150+ intact proteins in 45 minutes on a single tissue sample. The product portfolio includes: Miralys Probes (photocleavable mass-tag antibody reagents available as standard or dual-labeled), Miralys Panels (curated collections in TurboPlex pre-mixed or VersaPlex configurable formats for applications including Immuno-Oncology, Tissue Morphology, Lung Cancer, Breast Cancer, and Neurological research), and Miralys Kits (Starter Kits with light box and validation materials, plus Antibody Conjugation Kits allowing customers to create custom probes from 100+ available mass-tag codes). Supporting the reagent business is the MaxOmic Laboratory service offering full-service multiomic spatial imaging and analysis using proprietary software, capable of mapping 300+ lipids/metabolites, 100+ targeted proteins, 12+ targeted transcripts, and small molecule drugs on the same sample. Complementary technology platforms include Bead-AMS for proteome-wide drug screening and PC-PURE for photo-affinity biomarker enrichment. All products work in combination with Bruker MALDI mass spectrometry instrumentation (rapifleX and timsTOF fleX systems).

Product and service5 records
1Miralys Probes
CategoryReagents
Description

Patented photocleavable mass-tag antibody probes that are the core of the Miralys imaging system. Standard fully-validated probes are available for next-day shipment, with optional dual-label probes incorporating both a photocleavable mass tag and a fluorophore for correlative fluorescence and MALDI-MS imaging.

2Miralys Panels
CategoryReagents
Description

Ready-to-use curated collections of Miralys antibody imaging probes available in TurboPlex (pre-mixed, ready-to-use ultra-high-plex) and VersaPlex (individually-supplied configurable) formats. Includes panels for Immuno-Oncology (23-Plex), Tissue Morphology (14-Plex), Lung Cancer (21-Plex), Breast Cancer (20-Plex), Neurological (21-Plex), and Cancer Core (10-Plex).

3Miralys Starter Kit
CategoryKits
Description

Complete kit including a UV-Photocleavage light box, six-plex panel of probes (Neurology or Immunology tissue type), pre-stained and unstained FFPE tissue slides for validation and training, and all laboratory items needed to implement the Miralys MALDI HiPLEX-IHC workflow. Bundled with pre-staining and post-staining videoconferences with AmberGen Applications Scientists.

4Miralys Antibody Conjugation Kits
CategoryKits
Description

Kit containing proprietary photocleavable mass tags (PCMTs) and reagents for rapid one-step chemical conjugation of PCMT to customer-chosen antibodies. Over 100 different PCMTs are available for purchase to code antibodies.

5MaxOmic Laboratory Services
CategoryServices
Description

Full-service laboratory providing access to cutting-edge multiomic spatial biology techniques for imaging a wide range of molecules (proteins, lipids, glycans, metabolites, transcripts) and cells in their native tissue environment using Miralys technology. Maps 300+ lipids/metabolites, 100+ targeted proteins, up to 12 targeted transcripts, and small molecule drugs on the same sample on the same instrument. Delivers results with detailed project reports including descriptive statistics, pairwise colocalization analysis, clustering analysis, and thumbnail grid images.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership20 partners
Strategic tierSupportingTypeTechnology or Integration
Description

IHC-validated antibodies from Abcam are available for use in AmberGen's Miralys™ MALDI-IHC Imaging System. Abcam's catalog of validated antibodies expands the range of targets available to Miralys users.

Strategic tierSupportingTypeTechnology or Integration
Description

IHC-validated antibodies from Cell Signaling Technology are available for use in AmberGen's Miralys™ MALDI-IHC Imaging System. CST's validated antibody catalog provides researchers with additional target options for Miralys spatial imaging.

3MTAC at Washington University School of Medicine
Strategic tierSupportingTypeImplementation/ SI/ Consulting Partner
Description

The Mass Spectrometry Technology Access Center (MTAC) at the McDonnell Genome Institute at Washington University School of Medicine provides MALDI-IHC Imaging services using AmberGen's Miralys technology. This is a turnkey service option for first-time Miralys users who need data rapidly, such as for grant submissions.

ambergen.com
Strategic tierSupportingTypeImplementation/ SI/ Consulting Partner
Description

The TU Wien Research Group in Vienna, Austria provides MALDI-IHC Imaging services using AmberGen's Miralys technology, serving the European research community.

Strategic tierSupportingTypeImplementation/ SI/ Consulting Partner
Description

The University of Texas at Austin Mass Spec Imaging Facility provides MALDI-IHC Imaging services using AmberGen's Miralys technology, serving researchers in the Texas and surrounding regions.

6Proteomics Centre at University of Victoria
Strategic tierSupportingTypeImplementation/ SI/ Consulting Partner
Description

The Proteomics Centre at the University of Victoria in British Columbia, Canada provides MALDI-IHC Imaging services using AmberGen's Miralys technology, serving Canadian researchers.

ambergen.com
Strategic tierSupportingTypeChannel Partner/ Reseller/ Distributor
Description

Filgen is AmberGen's distributor for MALDI-IHC products in Japan, providing local sales, distribution, and customer support for Japanese researchers and institutions.

8MJ Science (Korea)
Strategic tierSupportingTypeChannel Partner/ Reseller/ Distributor
Description

MJ Science is AmberGen's distributor for MALDI-IHC products in Korea, handling local sales and distribution for Korean customers.

ambergen.com
Strategic tierSupportingTypeChannel Partner/ Reseller/ Distributor
Description

TrendBio is AmberGen's distributor for MALDI-IHC products in Australia, handling local sales and distribution for Australian customers.

Strategic tierSupportingTypeChannel Partner/ Reseller/ Distributor
Description

Verulam Scientific is AmberGen's distributor for MALDI-IHC Starter Kits and Reagents in the UK, handling local sales and distribution for UK customers.

Strategic tierSupportingTypeChannel Partner/ Reseller/ Distributor
Description

AmberGen's products are available through the ScienceExchange online marketplace, enabling researchers to purchase Miralys reagents through a familiar research procurement platform.

Strategic tierSupportingTypeChannel Partner/ Reseller/ Distributor
Description

AmberGen's products are available through the Scientist.com marketplace, enabling researchers to purchase Miralys reagents through an established scientific procurement platform.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

In 2011, SomaLogic, Inc. (now Standard BioTools) licensed AmberGen's PC-biotin Phosphoramidite technology for use with its innovative SomaScan® proteomics platform. This licensing agreement enables SomaLogic to use AmberGen's photocleavable reagent in SOMAmer® technology used to discover new biomarkers, representing a long-standing technology licensing relationship.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

AmberGen collaborated with Massachusetts General Hospital on the discovery of two novel autoantigen biomarkers for Primary Biliary Cirrhosis (PBC): Anti-Kelch-like 12 and Anti-Hexokinase 1. The resulting US Patent 8,852,956 was awarded jointly, and the biomarkers were licensed to INOVA Diagnostics for FDA clearance. The collaboration also included NIH-supported projects on blood-based immunodiagnostics.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

AmberGen collaborated with Boston Children's Hospital on a paper published in PLOS ONE describing application of AmberGen's PC-PURE™ technology to highly multiplex in vitro allergy testing (AllerBead™), using finger-stick blood for multiplex quantification of allergen-specific IgE.

16INOVA Diagnostics
Strategic tierSupportingTypeOEM/ Whitelabel/ Licensing Partner
Description

INOVA Diagnostics licensed two novel autoantigen biomarkers for Primary Biliary Cirrhosis (Anti-Kelch-like 12 and Anti-Hexokinase 1) discovered by AmberGen and MGH. Assays based on these biomarkers are currently undergoing FDA clearance. This represents a successful biomarker commercialization partnership.

ambergen.com
Strategic tierSupportingTypeOEM/ Whitelabel/ Licensing Partner
Description

Promega distributes AmberGen's fluorescent tRNA-based protein engineering technology (FluoroTect™ GreenLYS in vitro translation labeling system), representing a product licensing and distribution partnership.

Strategic tierSupportingTypeOEM/ Whitelabel/ Licensing Partner
Description

Thermo Fisher Scientific (through Fisher Scientific) sells AmberGen's PC-Biotin-NHS reagent, representing a product distribution partnership for AmberGen's photocleavable labeling reagents.

Strategic tierSupportingTypeOEM/ Whitelabel/ Licensing Partner
Description

Glen Research distributes AmberGen's Photocleavable Phosphoramidite DNA-labeling reagents, representing a product distribution partnership for AmberGen's DNA labeling technology.

Strategic tierMinorTypeOEM/ Whitelabel/ Licensing Partner
Description

Link Technologies Ltd. offers AmberGen's Photocleavable Phosphoramidite DNA-labeling reagents in Europe, providing an additional distribution channel for AmberGen's DNA labeling products in the European market.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

10x Genomics offers Xenium in-situ spatial gene expression and Visium spatial transcriptomics platforms targeting tissue-based multiomic profiling — directly competing with AmberGen's Miralys for high-plex spatial biology workflows in pharma and academic research.

TypeDirect peer
Description

NanoString's CosMx SMI and GeoMx Digital Spatial Profiling platforms are direct competitors in high-plex spatial tissue imaging — particularly relevant now that NanoString's spatial biology business sits within Bruker, AmberGen's strategic investor and instrument partner.

TypeDirect peer
Description

Akoya's Phenoptics (OPAL multiplex immunofluorescence) and PhenoCycler-Fusion platforms compete with Miralys for high-plex tissue biomarker imaging in immuno-oncology and tumor microenvironment profiling.

TypeEmerging player
Description

Ionpath's MIBI (Multiplexed Ion Beam Imaging) platform provides high-plex spatial proteomics using secondary ion mass spectrometry — a partial overlap with AmberGen's MALDI-MS-based Miralys approach for tissue biomarker imaging.

TypeBroad incumbent
Description

Standard BioTools offers the Hyperion Imaging System for mass cytometry-based spatial tissue imaging and operates the SomaScan proteomics platform — the latter uses AmberGen's licensed PC-biotin phosphoramidite chemistry, making them both a licensee and adjacent competitor.

TypeEmerging player
Description

Lunaphore's COMET platform delivers sequential multiplex immunofluorescence for high-plex tissue imaging — emerging competition in the same translational research and clinical pathology segment that Miralys targets.

TypeBroad incumbent
Description

Bruker is both AmberGen's strategic minority investor and the manufacturer of the rapifleX and timsTOF fleX MALDI-MS instruments on which Miralys depends — making it an indispensable partner and a broader incumbent in spatial biology mass spectrometry.

TypeBroad incumbent
Description

Miltenyi's MACSima and MACS Spatial Tissue Imaging platforms compete in automated high-plex immunofluorescence spatial biology, serving overlapping immuno-oncology and translational research customers as AmberGen.

TypeEmerging player
Description

Canopy's Cell DIVE and ChipCytometry platforms offer high-plex spatial tissue imaging — addressing similar tumor microenvironment and neuroscience applications as AmberGen's Miralys panels.

TypeEmerging player
Description

Resolve's Molecular Cartography platform provides subcellular spatial transcriptomics, targeting the same pharma translational research segment as Miralys but with a transcriptomics-led workflow.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AmberGen

Spatial Biology Imagingambergen.com

AmberGen commercializes the patented Miralys MALDI-IHC spatial biology platform, using Photocleavable Mass Tag chemistry to image 150+ proteins, metabolites, lipids, glycans, and drugs on a single tissue section, serving academic core facilities, pharma/biotech drug developers, and diagnostic reagent licensees worldwide.

What AmberGen does

AmberGen is a privately held, Boston-area biotechnology tools company founded in 1993 to commercialize photocleavable chemistry developed in Professor Kenneth Rothschild's laboratory at Boston University. Its core platform is the patented Miralys MALDI-IHC (Matrix-Assisted Laser Desorption/Ionization Immunohistochemistry) spatial biology imaging system, which uses Photocleavable Mass Tags (PCMTs) — peptide mass-tags attached to antibodies via photocleavable linkers — to enable simultaneous MALDI-MS detection of up to 150+ intact protein biomarkers in a single 45-minute scan, without iterative cycling. The platform is compatible with Bruker rapifleX and timsTOF fleX MALDI-MS instruments and works on both fresh frozen and FFPE tissue, supporting correlative immunofluorescence through optional dual-label probes and combining with native multiomic imaging of unlabeled metabolites, lipids, glycans, and small-molecule drugs on the same tissue section.

AmberGen monetizes the platform through three primary channels: (1) reagent sales — Miralys Probes, Miralys Panels (TurboPlex pre-mixed and VersaPlex configurable formats), Miralys Starter Kits (UV light box, 6-plex validation probes, FFPE slides, and complementary application-scientist onboarding), and Miralys Antibody Conjugation Kits covering 100 PCMT codes; (2) full-service MaxOmic Laboratory multiomic spatial biology imaging and analysis on a fee-for-service basis; and (3) technology licensing of its PC-Biotin, PC-Phosphoramidites, and PC-Linker chemistries to OEM partners including SomaLogic (now Standard BioTools), Promega, Thermo Fisher Scientific, Glen Research, and Link Technologies. Distribution is a hybrid direct/distributor model — direct sales to pharma, biotech, and academic core facilities in North America and globally, with regional distributors in Japan, Korea, Australia, and the UK, plus research-services marketplaces (ScienceExchange, Scientist.com) and a Miralys-enabled service-lab network at MTAC (Washington University), TU Wien, UT Austin, and the University of Victoria.

The company has been non-dilutively financed through approximately $11.5M of NIH SBIR grants across NIA, NCI, NIAID, and NIGMS, and accepted a strategic minority investment from Bruker Corporation in April 2022 alongside additional MassVentures-backed funding rounds of $100K (June 2022) and $200K (May 2023). Customer concentration is diversified across academic translational centers, pharma/biotech drug development teams, and reagent OEM licensees; segment focus spans neuroscience, immuno-oncology, and clinical pathology applications.

AmberGen firmographics

Firmographics
Name
AmberGen
Legal name
Ambergen Inc.
Website
https://ambergen.com
Company type
Private
Founded year
1993
Operating status
Operating
Headcount range
11–50 employees
Short description
AmberGen commercializes the patented Miralys MALDI-IHC spatial biology platform, using Photocleavable Mass Tag chemistry to image 150+ proteins, metabolites, lipids, glycans, and drugs on a single tissue section, serving academic core facilities, pharma/biotech drug developers, and diagnostic reagent licensees worldwide.
Ownership category
akta.pro rank

AmberGen industry classification

Industry
Product category
Spatial Biology Imaging
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAAMAI
Molecular Pathology & Tissue Biomarkers (IHC/ISH, digital pathology-linked markers)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAALAI
Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays)
SECONDARYHLAGANAB
Proteomics & Mass Spectrometry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)

Keywords

  • Spatial biology imaging
  • Mass spectrometry reagents
  • Photocleavable mass tags
  • Multiplex immunohistochemistry
  • Drug colocalization imaging

Where AmberGen is headquartered

Location

Headquarters

HQ city
Billerica
HQ country
United States
HQ region
North America

Offices1 record

Markets served

AmberGen business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Miralys Reagent Sales: Sale of Miralys imaging reagents including photocleavable mass-tag probes, pre-configured panels (TurboPlex™ pre-mixed and VersaPlex™ configurable formats), and antibody conjugation kits. Reagents are sold directly and through distributors in Japan, Korea, Australia, and the UK.
  2. MaxOmic Laboratory Services: AmberGen's full-service MaxOmic™ Laboratory provides multiomic spatial biology imaging and analysis as a service, including spatial proteomics, lipidomics, glycomics, metabolomics, and pharma imaging on the same sample. Results are delivered with a detailed project report including descriptive statistics, pairwise colocalization analysis, clustering analysis, and thumbnail grid images.
  3. Technology Licensing: Licensing of AmberGen's photocleavable technology (PC-biotin phosphoramidites, PC-Linkers) to third-party reagent companies such as SomaLogic (for the SomaScan proteomics platform), Promega (fluorescent tRNA products), Thermo-Fisher (PC-Biotin-NHS), Glen Research (phosphoramidite DNA-labeling reagents), and Link Technologies (European distribution).
  4. Starter Kits and Training Services: One-time sale of Miralys Starter Kits (UV photocleavage light box, 6-plex validation probe mix, pre-stained and unstained FFPE tissue slides) bundled with complimentary onboarding videoconferences and follow-up image review sessions. Additional on-site training sessions available for purchase.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goStarter Kit for new Miralys users

Go-to-market motion2 records

Distribution channels7 records

Marketing channels5 records

AmberGen product offering

Product offering

Core offering

AmberGen develops and sells the Miralys MALDI-IHC spatial biology imaging platform, including Photocleavable Mass Tag (PCMT) antibody probes, pre-configured panels, antibody conjugation kits, and starter kits that enable ultra-high-plex (150+ proteins) imaging of tissues on standard MALDI mass spectrometers. The company also operates the MaxOmic Laboratory, a fee-for-service offering that delivers full-service multiomic spatial imaging and analysis (proteins, lipids, glycans, metabolites, transcripts, and drugs on the same sample).

Product overview

AmberGen offers the Miralys platform as its core product line for spatial biology research. The platform centers on patented Photocleavable Mass Tag (PCMT) technology that enables hyperplex MALDI-IHC (Immunohistochemistry) imaging of up to 150+ intact proteins in 45 minutes on a single tissue sample. The product portfolio includes: Miralys Probes (photocleavable mass-tag antibody reagents available as standard or dual-labeled), Miralys Panels (curated collections in TurboPlex pre-mixed or VersaPlex configurable formats for applications including Immuno-Oncology, Tissue Morphology, Lung Cancer, Breast Cancer, and Neurological research), and Miralys Kits (Starter Kits with light box and validation materials, plus Antibody Conjugation Kits allowing customers to create custom probes from 100+ available mass-tag codes). Supporting the reagent business is the MaxOmic Laboratory service offering full-service multiomic spatial imaging and analysis using proprietary software, capable of mapping 300+ lipids/metabolites, 100+ targeted proteins, 12+ targeted transcripts, and small molecule drugs on the same sample. Complementary technology platforms include Bead-AMS for proteome-wide drug screening and PC-PURE for photo-affinity biomarker enrichment. All products work in combination with Bruker MALDI mass spectrometry instrumentation (rapifleX and timsTOF fleX systems).

Differentiator

Problem solved

Functional benefit

Brands

  • MaxOmic Laboratory: AmberGen's full-service laboratory providing cutting-edge multiomic spatial biology techniques for imaging a wide range of molecules and cells in their native tissue environment.
  • Miralys
  • TurboPlex
  • VersaPlex
  • PCMT (Photocleavable Mass Tag)
  • PC-Linker

Products and services

  • Miralys Probes Patented photocleavable mass-tag antibody probes that are the core of the Miralys imaging system. Standard fully-validated probes are available for next-day shipment, with optional dual-label probes incorporating both a photocleavable mass tag and a fluorophore for correlative fluorescence and MALDI-MS imaging.
  • Miralys Panels Ready-to-use curated collections of Miralys antibody imaging probes available in TurboPlex (pre-mixed, ready-to-use ultra-high-plex) and VersaPlex (individually-supplied configurable) formats. Includes panels for Immuno-Oncology (23-Plex), Tissue Morphology (14-Plex), Lung Cancer (21-Plex), Breast Cancer (20-Plex), Neurological (21-Plex), and Cancer Core (10-Plex).
  • Miralys Starter Kit Complete kit including a UV-Photocleavage light box, six-plex panel of probes (Neurology or Immunology tissue type), pre-stained and unstained FFPE tissue slides for validation and training, and all laboratory items needed to implement the Miralys MALDI HiPLEX-IHC workflow. Bundled with pre-staining and post-staining videoconferences with AmberGen Applications Scientists.
  • Miralys Antibody Conjugation Kits Kit containing proprietary photocleavable mass tags (PCMTs) and reagents for rapid one-step chemical conjugation of PCMT to customer-chosen antibodies. Over 100 different PCMTs are available for purchase to code antibodies.
  • MaxOmic Laboratory Services Full-service laboratory providing access to cutting-edge multiomic spatial biology techniques for imaging a wide range of molecules (proteins, lipids, glycans, metabolites, transcripts) and cells in their native tissue environment using Miralys technology. Maps 300+ lipids/metabolites, 100+ targeted proteins, up to 12 targeted transcripts, and small molecule drugs on the same sample on the same instrument. Delivers results with detailed project reports including descriptive statistics, pairwise colocalization analysis, clustering analysis, and thumbnail grid images.

Quantifiable outcome

  • 150+ intact protein biomarkers can be imaged in as fast as 45 minutes per 1 cm² tissue sample, with scan duration independent of multiplexity
  • +4 more outcomes

Companies that use AmberGen

Customer profile

Named customers7 records

Segments4 records

Ideal customer profiles4 records

AmberGen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

Feature6 records

AmberGen partnerships and signals

Strategic signal

Partnerships

20 partnerships are on record, tiered supporting, core and minor.

  • AbcamsupportingTechnology or IntegrationIHC-validated antibodies from Abcam are available for use in AmberGen's Miralys™ MALDI-IHC Imaging System. Abcam's catalog of validated antibodies expands the range of targets available to Miralys users.
  • Cell Signaling Technology (CST)supportingTechnology or IntegrationIHC-validated antibodies from Cell Signaling Technology are available for use in AmberGen's Miralys™ MALDI-IHC Imaging System. CST's validated antibody catalog provides researchers with additional target options for Miralys spatial imaging.
  • MTAC at Washington University School of MedicinesupportingImplementation/ SI/ Consulting PartnerThe Mass Spectrometry Technology Access Center (MTAC) at the McDonnell Genome Institute at Washington University School of Medicine provides MALDI-IHC Imaging services using AmberGen's Miralys technology. This is a turnkey service option for first-time Miralys users who need data rapidly, such as for grant submissions.
  • TU Wien Research Group for Mass Spectrometric Bio- and Polymer AnalysissupportingImplementation/ SI/ Consulting PartnerThe TU Wien Research Group in Vienna, Austria provides MALDI-IHC Imaging services using AmberGen's Miralys technology, serving the European research community.
  • UT Austin Mass Spec Imaging FacilitysupportingImplementation/ SI/ Consulting PartnerThe University of Texas at Austin Mass Spec Imaging Facility provides MALDI-IHC Imaging services using AmberGen's Miralys technology, serving researchers in the Texas and surrounding regions.
  • Proteomics Centre at University of VictoriasupportingImplementation/ SI/ Consulting PartnerThe Proteomics Centre at the University of Victoria in British Columbia, Canada provides MALDI-IHC Imaging services using AmberGen's Miralys technology, serving Canadian researchers.
  • Filgen (Japan)supportingChannel Partner/ Reseller/ DistributorFilgen is AmberGen's distributor for MALDI-IHC products in Japan, providing local sales, distribution, and customer support for Japanese researchers and institutions.
  • MJ Science (Korea)supportingChannel Partner/ Reseller/ DistributorMJ Science is AmberGen's distributor for MALDI-IHC products in Korea, handling local sales and distribution for Korean customers.
  • TrendBio (Australia)supportingChannel Partner/ Reseller/ DistributorTrendBio is AmberGen's distributor for MALDI-IHC products in Australia, handling local sales and distribution for Australian customers.
  • Verulam Scientific (UK)supportingChannel Partner/ Reseller/ DistributorVerulam Scientific is AmberGen's distributor for MALDI-IHC Starter Kits and Reagents in the UK, handling local sales and distribution for UK customers.
  • ScienceExchangesupportingChannel Partner/ Reseller/ DistributorAmberGen's products are available through the ScienceExchange online marketplace, enabling researchers to purchase Miralys reagents through a familiar research procurement platform.
  • Scientist.comsupportingChannel Partner/ Reseller/ DistributorAmberGen's products are available through the Scientist.com marketplace, enabling researchers to purchase Miralys reagents through an established scientific procurement platform.
  • SomaLogic (now Standard BioTools)coreOEM/ Whitelabel/ Licensing PartnerIn 2011, SomaLogic, Inc. (now Standard BioTools) licensed AmberGen's PC-biotin Phosphoramidite technology for use with its innovative SomaScan® proteomics platform. This licensing agreement enables SomaLogic to use AmberGen's photocleavable reagent in SOMAmer® technology used to discover new biomarkers, representing a long-standing technology licensing relationship.
  • Massachusetts General Hospital (MGH)coreStrategic or Co-development PartnerAmberGen collaborated with Massachusetts General Hospital on the discovery of two novel autoantigen biomarkers for Primary Biliary Cirrhosis (PBC): Anti-Kelch-like 12 and Anti-Hexokinase 1. The resulting US Patent 8,852,956 was awarded jointly, and the biomarkers were licensed to INOVA Diagnostics for FDA clearance. The collaboration also included NIH-supported projects on blood-based immunodiagnostics.
  • Boston Children's HospitalsupportingStrategic or Co-development PartnerAmberGen collaborated with Boston Children's Hospital on a paper published in PLOS ONE describing application of AmberGen's PC-PURE™ technology to highly multiplex in vitro allergy testing (AllerBead™), using finger-stick blood for multiplex quantification of allergen-specific IgE.
  • INOVA DiagnosticssupportingOEM/ Whitelabel/ Licensing PartnerINOVA Diagnostics licensed two novel autoantigen biomarkers for Primary Biliary Cirrhosis (Anti-Kelch-like 12 and Anti-Hexokinase 1) discovered by AmberGen and MGH. Assays based on these biomarkers are currently undergoing FDA clearance. This represents a successful biomarker commercialization partnership.
  • PromegasupportingOEM/ Whitelabel/ Licensing PartnerPromega distributes AmberGen's fluorescent tRNA-based protein engineering technology (FluoroTect™ GreenLYS in vitro translation labeling system), representing a product licensing and distribution partnership.
  • Thermo Fisher ScientificsupportingOEM/ Whitelabel/ Licensing PartnerThermo Fisher Scientific (through Fisher Scientific) sells AmberGen's PC-Biotin-NHS reagent, representing a product distribution partnership for AmberGen's photocleavable labeling reagents.
  • Glen ResearchsupportingOEM/ Whitelabel/ Licensing PartnerGlen Research distributes AmberGen's Photocleavable Phosphoramidite DNA-labeling reagents, representing a product distribution partnership for AmberGen's DNA labeling technology.
  • Link Technologies Ltd.minorOEM/ Whitelabel/ Licensing PartnerLink Technologies Ltd. offers AmberGen's Photocleavable Phosphoramidite DNA-labeling reagents in Europe, providing an additional distribution channel for AmberGen's DNA labeling products in the European market.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

AmberGen competitors and assessment

Company assessment

Direct peers

  • 10x Genomics: 10x Genomics offers Xenium in-situ spatial gene expression and Visium spatial transcriptomics platforms targeting tissue-based multiomic profiling — directly competing with AmberGen's Miralys for high-plex spatial biology workflows in pharma and academic research.
  • NanoString Technologies (a Bruker company): NanoString's CosMx SMI and GeoMx Digital Spatial Profiling platforms are direct competitors in high-plex spatial tissue imaging — particularly relevant now that NanoString's spatial biology business sits within Bruker, AmberGen's strategic investor and instrument partner.
  • Akoya Biosciences: Akoya's Phenoptics (OPAL multiplex immunofluorescence) and PhenoCycler-Fusion platforms compete with Miralys for high-plex tissue biomarker imaging in immuno-oncology and tumor microenvironment profiling.

Emerging players

  • Ionpath: Ionpath's MIBI (Multiplexed Ion Beam Imaging) platform provides high-plex spatial proteomics using secondary ion mass spectrometry — a partial overlap with AmberGen's MALDI-MS-based Miralys approach for tissue biomarker imaging.
  • Lunaphore: Lunaphore's COMET platform delivers sequential multiplex immunofluorescence for high-plex tissue imaging — emerging competition in the same translational research and clinical pathology segment that Miralys targets.
  • Canopy Biosciences: Canopy's Cell DIVE and ChipCytometry platforms offer high-plex spatial tissue imaging — addressing similar tumor microenvironment and neuroscience applications as AmberGen's Miralys panels.
  • Resolve Biosciences: Resolve's Molecular Cartography platform provides subcellular spatial transcriptomics, targeting the same pharma translational research segment as Miralys but with a transcriptomics-led workflow.

Broad incumbents

  • Standard BioTools (formerly Fluidigm): Standard BioTools offers the Hyperion Imaging System for mass cytometry-based spatial tissue imaging and operates the SomaScan proteomics platform — the latter uses AmberGen's licensed PC-biotin phosphoramidite chemistry, making them both a licensee and adjacent competitor.
  • Bruker Corporation: Bruker is both AmberGen's strategic minority investor and the manufacturer of the rapifleX and timsTOF fleX MALDI-MS instruments on which Miralys depends — making it an indispensable partner and a broader incumbent in spatial biology mass spectrometry.
  • Miltenyi Biotec: Miltenyi's MACSima and MACS Spatial Tissue Imaging platforms compete in automated high-plex immunofluorescence spatial biology, serving overlapping immuno-oncology and translational research customers as AmberGen.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

AmberGen social profiles

Digital presence

AmberGen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AmberGen leadership team

Management profile

Number of profiles

Profiles5 records

AmberGen funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AmberGen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AmberGen

What does AmberGen do?

AmberGen develops and sells the Miralys MALDI-IHC spatial biology imaging platform, including Photocleavable Mass Tag (PCMT) antibody probes, pre-configured panels, antibody conjugation kits, and starter kits that enable ultra-high-plex (150+ proteins) imaging of tissues on standard MALDI mass spectrometers. The company also operates the MaxOmic Laboratory, a fee-for-service offering that delivers full-service multiomic spatial imaging and analysis (proteins, lipids, glycans, metabolites, transcripts, and drugs on the same sample).

Is AmberGen a public or private company?

AmberGen is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was AmberGen founded?

AmberGen was founded in 1993. It employs 11 to 50 people.

Where is AmberGen based?

AmberGen is headquartered in Billerica, United States, in the North America region.

How does AmberGen make money?

Four revenue lines are on record. Miralys Reagent Sales are the primary driver. The others are maxOmic Laboratory Services, technology Licensing and starter Kits and Training Services.

Who are AmberGen's main competitors?

Direct peers on record are 10x Genomics, NanoString Technologies (a Bruker company) and Akoya Biosciences. Emerging players are Ionpath, Lunaphore, Canopy Biosciences and Resolve Biosciences. Broad incumbents are Standard BioTools (formerly Fluidigm), Bruker Corporation and Miltenyi Biotec.

Does AmberGen have an API?

No public API is recorded for AmberGen.

What industry is AmberGen in?

AmberGen's product category is Spatial Biology Imaging. Its primary akta.pro industry code is HLAAAMAI, Molecular Pathology & Tissue Biomarkers (IHC/ISH, digital pathology-linked markers), with a secondary code of HLAAALAI, Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales